MBX Biosciences announces sustained one-year data for once-weekly canvuparatide in hypoparathyroidism

MBX Biosciences, Inc.

57% of evaluable patients (31/54) achieved responder status at one year, comparable to 63% at 12 weeks in Phase 2 Avail trial.
PK profile supports once-weekly dosing with peak-to-trough ratio of ~1.3 over one week, ensuring stable exposure.
Mean eGFR increased from baseline at Week 12 and remained improved through one year; urine calcium decreased and stayed normal.
Canvuparatide was well tolerated; no treatment-related serious adverse events; injection site reactions in 10% of OLE patients.
Phase 3 pivotal trial remains on track to initiate in Q3 2026; 90% of OLE patients continued treatment at one year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.